Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 117

1.

Author response: Rare side effects of alemtuzumab remind us of the need for postmarketing surveillance.

Muraro PA, Scolding NJ, Fox RJ.

Neurology. 2019 Mar 19;92(12):586. doi: 10.1212/WNL.0000000000007128. No abstract available.

PMID:
30886076
2.

Dysregulation of Mesenchymal Stromal Cell Antioxidant Responses in Progressive Multiple Sclerosis.

Redondo J, Sarkar P, Kemp K, Heesom KJ, Wilkins A, Scolding NJ, Rice CM.

Stem Cells Transl Med. 2018 Oct;7(10):748-758. doi: 10.1002/sctm.18-0045. Epub 2018 Jul 31.

3.

Advising patients seeking stem cell interventions for multiple sclerosis.

von Wunster B, Bailey S, Wilkins A, Marks DI, Scolding NJ, Rice CM.

Pract Neurol. 2018 Dec;18(6):472-476. doi: 10.1136/practneurol-2018-001956. Epub 2018 May 30.

PMID:
29848512
4.

Rare side effects of alemtuzumab remind us of the need for postmarketing surveillance.

Muraro PA, Scolding NJ, Fox RJ.

Neurology. 2018 May 1;90(18):819-820. doi: 10.1212/WNL.0000000000005409. Epub 2018 Mar 30. No abstract available.

PMID:
29602911
5.

Aberrant cerebellar Purkinje cell function repaired in vivo by fusion with infiltrating bone marrow-derived cells.

Kemp KC, Dey R, Verhagen J, Scolding NJ, Usowicz MM, Wilkins A.

Acta Neuropathol. 2018 Jun;135(6):907-921. doi: 10.1007/s00401-018-1833-z. Epub 2018 Mar 14.

6.

Bone marrow transplantation stimulates neural repair in Friedreich's ataxia mice.

Kemp KC, Hares K, Redondo J, Cook AJ, Haynes HR, Burton BR, Pook MA, Rice CM, Scolding NJ, Wilkins A.

Ann Neurol. 2018 Apr;83(4):779-793. doi: 10.1002/ana.25207.

7.

Cell-based therapeutic strategies for multiple sclerosis.

Scolding NJ, Pasquini M, Reingold SC, Cohen JA; International Conference on Cell-Based Therapies for Multiple Sclerosis; International Conference on Cell-Based Therapies for Multiple Sclerosis; International Conference on Cell-Based Therapies for Multiple Sclerosis.

Brain. 2017 Nov 1;140(11):2776-2796. doi: 10.1093/brain/awx154. Review.

8.

Reduced neuroprotective potential of the mesenchymal stromal cell secretome with ex vivo expansion, age and progressive multiple sclerosis.

Sarkar P, Redondo J, Kemp K, Ginty M, Wilkins A, Scolding NJ, Rice CM.

Cytotherapy. 2018 Jan;20(1):21-28. doi: 10.1016/j.jcyt.2017.08.007. Epub 2017 Sep 13.

9.

Reduced cellularity of bone marrow in multiple sclerosis with decreased MSC expansion potential and premature ageing in vitro.

Redondo J, Sarkar P, Kemp K, Virgo PF, Pawade J, Norton A, Emery DC, Guttridge MG, Marks DI, Wilkins A, Scolding NJ, Rice CM.

Mult Scler. 2018 Jun;24(7):919-931. doi: 10.1177/1352458517711276. Epub 2017 May 26.

10.

Cell Therapy for Multiple Sclerosis.

Sarkar P, Rice CM, Scolding NJ.

CNS Drugs. 2017 Jun;31(6):453-469. doi: 10.1007/s40263-017-0429-9. Review.

PMID:
28397112
11.

Cytokine therapy-mediated neuroprotection in a Friedreich's ataxia mouse model.

Kemp KC, Cerminara N, Hares K, Redondo J, Cook AJ, Haynes HR, Burton BR, Pook M, Apps R, Scolding NJ, Wilkins A.

Ann Neurol. 2017 Feb;81(2):212-226. doi: 10.1002/ana.24846.

12.

Neurosarcoidosis: a clinical approach to diagnosis and management.

Ibitoye RT, Wilkins A, Scolding NJ.

J Neurol. 2017 May;264(5):1023-1028. doi: 10.1007/s00415-016-8336-4. Epub 2016 Nov 22. Review.

13.

Percutaneous Endoscopic Gastrostomy Tube Insertion in Neurodegenerative Disease: A Retrospective Study and Literature Review.

Sarkar P, Cole A, Scolding NJ, Rice CM.

Clin Endosc. 2017 May;50(3):270-278. doi: 10.5946/ce.2016.106. Epub 2016 Oct 13.

14.

Erdheim-Chester disease: 25-year history with early CNS involvement.

Rice CM, Hall CA, McCoubrie P, Renowden SA, Cohen N, Scolding NJ.

BMJ Case Rep. 2016 Oct 4;2016. pii: bcr2016216747. doi: 10.1136/bcr-2016-216747.

15.

Ovarioleukodystrophy due to EIF2B5 mutations.

Ibitoye RT, Renowden SA, Faulkner HJ, Scolding NJ, Rice CM.

Pract Neurol. 2016 Dec;16(6):496-499. doi: 10.1136/practneurol-2016-001382. Epub 2016 Sep 20.

PMID:
27651498
16.

Erratum to: 'Purkinje cell injury, structural plasticity and fusion in patients with Friedreich's ataxia'.

Kemp KC, Cook AJ, Redondo J, Kurian KM, Scolding NJ, Wilkins A.

Acta Neuropathol Commun. 2016 Jun 30;4(1):67. No abstract available.

17.

Purkinje cell injury, structural plasticity and fusion in patients with Friedreich's ataxia.

Kemp KC, Cook AJ, Redondo J, Kurian KM, Scolding NJ, Wilkins A.

Acta Neuropathol Commun. 2016 May 23;4(1):53. doi: 10.1186/s40478-016-0326-3. Erratum in: Acta Neuropathol Commun. 2016;4(1):67.

18.

Intracranial spread of IgG4-related disease via skull base foramina.

Rice CM, Spencer T, Bunea G, Scolding NJ, Sloan P, Nath U.

Pract Neurol. 2016 Jun;16(3):240-2. doi: 10.1136/practneurol-2015-001315. Epub 2016 Feb 8.

PMID:
26856357
19.

Tumefactive demyelination presenting during bevacizumab treatment.

Rice CM, Rossiter D, Fehmi J, Stevens JC, Renowden SA, Cohen N, Bailey C, Scolding NJ.

BMJ Case Rep. 2015 Dec 16;2015. pii: bcr2015212173. doi: 10.1136/bcr-2015-212173.

20.

Alemtuzumab for multiple sclerosis: Long term follow-up in a multi-centre cohort.

Willis MD, Harding KE, Pickersgill TP, Wardle M, Pearson OR, Scolding NJ, Smee J, Robertson NP.

Mult Scler. 2016 Aug;22(9):1215-23. doi: 10.1177/1352458515614092. Epub 2015 Oct 29.

PMID:
26514979
21.

Assessment of bone marrow-derived Cellular Therapy in progressive Multiple Sclerosis (ACTiMuS): study protocol for a randomised controlled trial.

Rice CM, Marks DI, Ben-Shlomo Y, Evangelou N, Morgan PS, Metcalfe C, Walsh P, Kane NM, Guttridge MG, Miflin G, Blackmore S, Sarkar P, Redondo J, Owen D, Cottrell DA, Wilkins A, Scolding NJ.

Trials. 2015 Oct 14;16:463. doi: 10.1186/s13063-015-0953-1.

22.

Repeat infusion of autologous bone marrow cells in multiple sclerosis: protocol for a phase I extension study (SIAMMS-II).

Rice CM, Marks DI, Walsh P, Kane NM, Guttridge MG, Redondo J, Sarkar P, Owen D, Wilkins A, Scolding NJ.

BMJ Open. 2015 Sep 11;5(9):e009090. doi: 10.1136/bmjopen-2015-009090.

23.

Idiopathic hypereosinophilic syndrome: a new cause of vasculitis of the central nervous system.

Rice CM, Kurian KM, Renowden S, Whiteway A, Price C, Scolding NJ.

J Neurol. 2015 May;262(5):1354-9. doi: 10.1007/s00415-015-7720-9. Epub 2015 Apr 7.

PMID:
25843450
24.

Preclinical development and first-in-human study of ATX-MS-1467 for immunotherapy of MS.

Streeter HB, Rigden R, Martin KF, Scolding NJ, Wraith DC.

Neurol Neuroimmunol Neuroinflamm. 2015 Mar 12;2(3):e93. doi: 10.1212/NXI.0000000000000093. eCollection 2015 Jun.

25.

Immune reconstitution and treatment response in multiple sclerosis following alemtuzumab.

Robertson NP, Scolding NJ.

Neurology. 2014 Jun 17;82(24):2150-1. doi: 10.1212/WNL.0000000000000530. Epub 2014 May 16. No abstract available.

PMID:
24838787
26.

Cell therapy for multiple sclerosis: an evolving concept with implications for other neurodegenerative diseases.

Rice CM, Kemp K, Wilkins A, Scolding NJ.

Lancet. 2013 Oct 5;382(9899):1204-13. doi: 10.1016/S0140-6736(13)61810-3.

PMID:
24095194
27.

Primary progressive multiple sclerosis: progress and challenges.

Rice CM, Cottrell D, Wilkins A, Scolding NJ.

J Neurol Neurosurg Psychiatry. 2013 Oct;84(10):1100-6. doi: 10.1136/jnnp-2012-304140. Epub 2013 Feb 16. Review.

PMID:
23418213
28.

Mitochondrial sirtuins--a new therapeutic target for repair and protection in multiple sclerosis.

Rice CM, Sun M, Kemp K, Gray E, Wilkins A, Scolding NJ.

Eur J Neurosci. 2012 Jun;35(12):1887-93. doi: 10.1111/j.1460-9568.2012.08150.x. Review.

PMID:
22708600
29.

Brain biopsy in benign neurological disease.

Gilkes CE, Love S, Hardie RJ, Edwards RJ, Scolding NJ, Rice CM.

J Neurol. 2012 May;259(5):995-1000. doi: 10.1007/s00415-012-6455-0. Epub 2012 Feb 24.

PMID:
22361977
30.

Human bone marrow mesenchymal stem cells protect catecholaminergic and serotonergic neuronal perikarya and transporter function from oxidative stress by the secretion of glial-derived neurotrophic factor.

Whone AL, Kemp K, Sun M, Wilkins A, Scolding NJ.

Brain Res. 2012 Jan 11;1431:86-96. doi: 10.1016/j.brainres.2011.10.038. Epub 2011 Oct 28.

PMID:
22143094
31.

Brain biopsy in cryptogenic neurological disease.

Rice CM, Gilkes CE, Teare E, Hardie RJ, Scolding NJ, Edwards RJ.

Br J Neurosurg. 2011 Oct;25(5):614-20. doi: 10.3109/02688697.2010.551677. Epub 2011 Apr 18.

PMID:
21501048
32.

Cerebral ischaemia in the context of improving, steroid-treated pneumococcal meningitis.

Rice CM, Ramamoorthi M, Renowden SA, Heywood P, Whone AL, Scolding NJ.

QJM. 2012 May;105(5):473-5. doi: 10.1093/qjmed/hcr056. Epub 2011 Apr 14. No abstract available.

PMID:
21493690
33.

Human mesenchymal stem cells infiltrate the spinal cord, reduce demyelination, and localize to white matter lesions in experimental autoimmune encephalomyelitis.

Gordon D, Pavlovska G, Uney JB, Wraith DC, Scolding NJ.

J Neuropathol Exp Neurol. 2010 Nov;69(11):1087-95. doi: 10.1097/NEN.0b013e3181f97392.

PMID:
20940628
34.

Neurological picture. Vertebral sarcoidosis mimicking metastases.

Rice CM, Beric V, Love S, Scolding NJ.

J Neurol Neurosurg Psychiatry. 2011 Feb;82(2):188. doi: 10.1136/jnnp.2009.204636. Epub 2010 Jun 22. No abstract available.

PMID:
20573613
35.

Long-term beta interferon in MS: safe, but what effect on disability?

Scolding NJ.

J Neurol Neurosurg Psychiatry. 2010 Aug;81(8):825-6. doi: 10.1136/jnnp.2010.208017. Epub 2010 Jun 22. No abstract available.

PMID:
20571040
36.

Safety and feasibility of autologous bone marrow cellular therapy in relapsing-progressive multiple sclerosis.

Rice CM, Mallam EA, Whone AL, Walsh P, Brooks DJ, Kane N, Butler SR, Marks DI, Scolding NJ.

Clin Pharmacol Ther. 2010 Jun;87(6):679-85. doi: 10.1038/clpt.2010.44. Epub 2010 May 5.

PMID:
20445531
37.

A window of opportunity for no treatment in early multiple sclerosis?

Gilmore CP, Cottrell DA, Scolding NJ, Wingerchuk DM, Weinshenker BG, Boggild M.

Mult Scler. 2010 Jun;16(6):756-9. doi: 10.1177/1352458510366014. Epub 2010 Apr 28. No abstract available.

PMID:
20427417
38.

Adult human mesenchymal cells proliferate and migrate in response to chemokines expressed in demyelination.

Rice CM, Scolding NJ.

Cell Adh Migr. 2010 Apr-Jun;4(2):235-40. Epub 2010 Apr 3.

39.

Neurolymphomatosis mimicking neurosarcoidosis: a case report.

Santos E, Scolding NJ.

J Med Case Rep. 2010 Jan 12;4:5. doi: 10.1186/1752-1947-4-5.

40.

Neurolupus.

Joseph FG, Scolding NJ.

Pract Neurol. 2010 Feb;10(1):4-15. doi: 10.1136/jnnp.2009.200071. Review.

PMID:
20130291
41.

Very long chain fatty acid levels in patients diagnosed with multiple sclerosis.

Wilkins A, Ingram G, Brown A, Jardine P, Steward CG, Robertson NP, Scolding NJ.

Mult Scler. 2009 Dec;15(12):1525-7. doi: 10.1177/1352458509351731. Epub 2009 Nov 13.

PMID:
19965514
42.

Multipotent adult progenitor cell isolation and proliferation in cytokine and serum-free medium conditioned by rat B104 cells.

Rice CM, Clavel C, Mazo M, Prosper F, Scolding NJ.

Br J Haematol. 2010 Feb;148(3):441-4. doi: 10.1111/j.1365-2141.2009.07986.x. Epub 2009 Nov 30.

PMID:
19961484
43.

Central nervous system vasculitis.

Scolding NJ.

Semin Immunopathol. 2009 Nov;31(4):527-36. doi: 10.1007/s00281-009-0183-2. Epub 2009 Nov 12. Review.

PMID:
19908043
44.

Serial retinal fluorescein angiography and immune therapy in Susac's syndrome.

Mallam B, Damato EM, Scolding NJ, Bailey C.

J Neurol Sci. 2009 Oct 15;285(1-2):230-4. doi: 10.1016/j.jns.2009.06.008. Epub 2009 Jul 5.

PMID:
19577774
45.

Neural cell transplantation: methods and protocols. Preface.

Scolding NJ, Gordon D.

Methods Mol Biol. 2009;549:v. No abstract available.

PMID:
19514140
46.

Human mesenchymal stem cell culture for neural transplantation.

Gordon D, Scolding NJ.

Methods Mol Biol. 2009;549:103-18. doi: 10.1007/978-1-60327-931-4_8.

PMID:
19378199
47.

Adult stem cells for the treatment of neurological disease.

Rice CM, Scolding NJ.

Methods Mol Biol. 2009;549:17-32. doi: 10.1007/978-1-60327-931-4_2.

PMID:
19378193
48.

Mesenchymal stem cells and neurodegenerative disease.

Whone AL, Scolding NJ.

Clin Pharmacol Ther. 2009 Jan;85(1):19-20. doi: 10.1038/clpt.2008.205.

PMID:
19092766
49.

Neurosarcoidosis: a study of 30 new cases.

Joseph FG, Scolding NJ.

J Neurol Neurosurg Psychiatry. 2009 Mar;80(3):297-304. doi: 10.1136/jnnp.2008.151977. Epub 2008 Oct 31.

PMID:
18977817
50.

Treatment of refractory neurosarcoidosis with Infliximab.

Santos E, Shaunak S, Renowden S, Scolding NJ.

J Neurol Neurosurg Psychiatry. 2010 Mar;81(3):241-6. doi: 10.1136/jnnp.2008.149989. Epub 2008 Oct 31.

PMID:
18977810

Supplemental Content

Loading ...
Support Center